Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL990691 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2442891 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2442893 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL236214 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL617118 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8512218 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29317 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL1559600 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2030143 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL940320 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-11656235-B2 | DNA aptamer-cyanine complexes as mephedrone and cannabinoid colorimetric sensors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230054132-A1 | DNA APTAMER-CYANINE COMPLEXES AS GENERIC COLORIMETRIC SENSORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-02-23 | — | — | US | disclosed |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | INHERIS BIOPHARMA INC (US) | 2020-03-12 | — | — | US | disclosed |
| CN-105503889-B | Oligomer-opioid agonist conjugates | 尼克塔治疗公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-10143690-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2018-12-04 | — | — | US | disclosed |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| CN-102159249-A | Pegylated opioids with low potential for abuse | NEKTAR THERAPEUTICS | 2011-08-17 | — | — | CN | disclosed |
| WO-2011088140-A1 | PEGYLATED OPIOIDS WITH LOW POTENTIAL FOR ABUSE AND SIDE EFFECTS | NEKTAR THERAPEUTICS (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2340044-A1 | PEGYLATED OPIOIDS WITH LOW POTENTIAL FOR ABUSE | Nektar Therapeutics (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2011011543-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010033195-A1 | PEGYLATED OPIOIDS WITH LOW POTENTIAL FOR ABUSE | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7060293-B1 | Powder-layered oral dosage forms | PURDUE PHARMA (CA) | 2006-06-13 | — | — | US | disclosed |
| EP-0711152-B1 | POWDER-LAYERED ORAL DOSAGE FORMS | EURO CELTIQUE SA (LU) | 2002-12-04 | — | — | EP | disclosed |
| US-4064228-A | Antigens and immunoassays for morphine and related 3-oxybenzomorphan compounds | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10143690-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.